Loading...
01/11 08:25
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Ceribell's earnings call presents a positive outlook with raised revenue guidance, strong gross margins, and strategic supply chain adjustments. Their market expansion into pediatrics and neonates, coupled with a new 510(k) clearance, enhances growth prospects. While competition and IP litigation pose risks, they haven't significantly impacted performance. The Q&A section reveals optimism about account growth and strategic partnerships, with some concerns about resource limitations and competition. Overall, the company's strategic initiatives and optimistic guidance suggest a positive stock price movement over the next two weeks.
Total Revenue $22.6 million for Q3 2025, a 31% increase from $17.2 million in Q3 2024. The increase is primarily driven by increased adoption of the Ceribell system across new and existing accounts.
Product Revenue $17 million for Q3 2025, a 28% increase from $13.3 million in Q3 2024. The growth was achieved despite abnormally high purchases relative to usage in Q3 2024, which led to excess product revenue during the comparison period.
Subscription Revenue $5.6 million for Q3 2025, a 44% increase from $3.9 million in Q3 2024. This reflects deeper penetration and increased usage per account year-over-year.
Gross Margin 88% for Q3 2025, compared to 87% in Q3 2024. The increase is attributed to operational efficiencies, though future margins may be impacted by tariffs on products originating in China.
Operating Expenses $34.6 million for Q3 2025, a 39% increase from $24.9 million in Q3 2024. The rise is due to investments in the commercial organization, increased headcount, legal expenses, and costs related to operating as a public company.
Net Loss $13.5 million for Q3 2025, compared to $10.4 million in Q3 2024. The increase in net loss is attributed to higher operating expenses and investments in growth initiatives.
Cash, Cash Equivalents, and Marketable Securities $168.5 million as of September 30, 2025. The company remains confident in achieving cash flow breakeven without raising additional capital.
Pediatric Clarity: Received 510(k) clearance for pediatric population, making it the only seizure detection algorithm cleared for patients 1 year and older. Pilot ongoing with full launch anticipated next year.
Neonatal Application of Clarity: Development on track with anticipated market launch in 2026. Hardware already launched at multiple sites.
Delirium Algorithm: Development progressing as planned, targeting a market with no commercially available diagnostic device for ICU patients.
Market Opportunity: Current addressable market for seizure detection is $2 billion, with an additional $400 million from pediatric and neonatal products.
Expansion into VA System: Received FedRAMP High Authorization, providing access to nearly 200 VA hospitals. VA system plans to expand usage of Ceribell system.
Revenue Growth: Q3 2025 revenue was $22.6 million, a 31% increase year-over-year. Full-year 2025 revenue guidance raised to $87-$89 million, representing 34% growth at midpoint.
Account Growth: Active accounts increased to 615 as of September 30, 2025, marking the largest sequential increase since becoming a public company.
Gross Margin: Maintained gross margin of 88% in Q3 2025, with mid-80% range expected for full year 2026.
Point-of-Care EEG Standardization: Focused on establishing point-of-care EEG as a new standard of care for seizure management in acute care settings.
Multimodal System Development: Plans to expand detection capabilities to conditions like delirium and stroke, aiming to make EEG a vital sign in acute care.
Regulatory and Tariff Risks: The company faces increased tariffs on products originating in China, which could impact gross margins. Although steps have been taken to establish a manufacturing line in Vietnam, the company remains exposed to potential changes in trade policies.
Supply Chain Disruptions: The company has taken steps to strengthen its supply chain by diversifying manufacturing locations, but any disruptions in these new facilities could impact operations and product availability.
Market Penetration Challenges: Despite growth, the company is only 3% penetrated into its core market in the U.S., with over 5,000 hospitals yet to adopt its system. Expanding market penetration remains a significant challenge.
Operational Costs: Operating expenses have increased by 39% year-over-year, driven by investments in commercial organization, headcount expansion, and legal expenses. This could pressure financial performance if revenue growth slows.
Cash Flow and Financial Sustainability: The company reported a net loss of $13.5 million for Q3 2025 and is not yet cash flow positive. While it has sufficient cash reserves, achieving cash flow breakeven is critical to long-term sustainability.
Competitive Pressures: The company operates in a competitive market and must continue to invest in product development and provider education to maintain its leadership position.
Adoption and Utilization Risks: The success of the Ceribell system depends on its adoption and utilization by hospitals. Delays in adoption or lower-than-expected utilization rates could impact revenue growth.
Product Development Risks: The company is investing in new products for pediatric and neonatal populations, as well as algorithms for conditions like delirium and stroke. Delays or failures in these developments could hinder market expansion.
Full Year 2025 Revenue Guidance: Ceribell has raised its full-year 2025 revenue guidance to $87 million to $89 million, representing 34% year-over-year growth at the midpoint.
Market Opportunity Expansion: The addition of pediatric and neonatal products is expected to expand the current addressable market opportunity of $2 billion by approximately $400 million, with a full launch anticipated next year.
Neonatal Application Development: The neonatal application of Clarity is on track for market introduction in 2026.
Delirium Algorithm Development: Development of a delirium algorithm remains on track, targeting a market with no commercially available diagnostic device. Further details on the opportunity and commercial strategy are expected in the coming quarters.
Gross Margin Outlook: Gross margins are expected to remain in the mid-80% range for the full year 2026, assuming no changes to proposed tariffs.
Revenue Growth Drivers: Revenue growth is driven by increased adoption of the Ceribell system across new and existing accounts, with a healthy backlog of accounts issuing purchase orders.
The selected topic was not discussed during the call.
Ceribell's earnings call presents a positive outlook with raised revenue guidance, strong gross margins, and strategic supply chain adjustments. Their market expansion into pediatrics and neonates, coupled with a new 510(k) clearance, enhances growth prospects. While competition and IP litigation pose risks, they haven't significantly impacted performance. The Q&A section reveals optimism about account growth and strategic partnerships, with some concerns about resource limitations and competition. Overall, the company's strategic initiatives and optimistic guidance suggest a positive stock price movement over the next two weeks.
The earnings call summary indicates positive developments such as improved gross margins due to supply chain diversification, effective cost management, and promising product launches. The Q&A reveals management's strategic focus on market expansion and addressing challenges, although some responses lack specificity. Overall, the company's initiatives and optimistic outlook, despite some uncertainties, suggest a positive sentiment. This, combined with the potential for margin improvements and market expansion, points to a likely positive stock price movement over the next two weeks.
The company reported significant revenue growth and improved gross margins, indicating strong financial performance. Despite increased operating expenses leading to a net loss, the guidance remains optimistic with continued investments in growth. The Q&A revealed some uncertainties about future guidance and FDA submissions, but the overall market strategy and expansion plans are positive. The stock price is likely to react positively over the next two weeks, especially given the record revenue growth and optimistic outlook for 2025.
The earnings report shows strong revenue growth and improved gross margins, suggesting positive financial performance. Despite increased operating expenses and net losses, the company maintains a solid cash position post-IPO. The Q&A indicates strategic investments in sales infrastructure and R&D, with a focus on future growth. While there are concerns about supply chain tariffs and unclear FDA submission details, the overall sentiment is optimistic, with expectations of accelerated growth post-2025. Given these factors, the stock is likely to experience a positive movement in the near term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
